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Abstract: Background: Fish is consumed as food worldwide and is considered as a rich source of essential nutri-
ents required for a healthy life. Supplementation with fish oil has been adopted as a solution to prevent or cure 
many pathophysiological states and diseases by both the professionals and the civil population. The beneficial 
effects are, however, being questioned, as some controversial results were obtained in clinical and population 
studies.  
Methods: Critical evaluation of studies regarding known effects of fish oil, both in favour of its consumption and 
related controversies.  
Results: From the literature review, contradictory allegations about the positive action of the fish oil on human 
health emerged, so that a clear line about its beneficial effect cannot be withdrawn.  
Conclusion: Scientific results on the application of fish oil should be taken with caution as there is still no stan-
dardised approach in testing its effects and there are significantly different baselines in respect to nutritional and 
other lifestyle habits of different populations.  
Keywords: Fish oil, ω-3PUFA, CVD, diabetes, cancer, controversies. 
1. INTRODUCTION 
 Fish is consumed as food worldwide and is considered as a rich 
source of the essential macro- and micro-nutrients required for a 
healthy life [1]. It is the richest source of vitamin D in its natural 
form [2] and it contains high-quality proteins and essential fatty 
acids (FA). Oil derived from fish is widely used for both preventive 
and therapeutic purposes, as it was shown that its application may 
ameliorate some disease states. Consumption of fish oil (FO) was, 
however, also associated with certain health disturbances, leading 
to a debate questioning its beneficial potential. The known effects 
of FO, both in favour of its consumption and those which alert to be 
more cautious are reviewed in this article. 
2. FO AND ITS FATTY ACIDS  
 If the fat content in fish is low (1-2 %), the fish is called 
“white”, and if it is high (5-20 %), the fish is called “oily” or “blue” 
[3]. Both types of fish contain the same fats that are essential for 
human health. FO contains ω-3 (omega-3) polyunsaturated FAs 
(PUFAs) [4]. The most abundant ω-3 PUFAs in fish are EPA (ei-
cosapentaenoic acid, 20:5) and DHA (docosahexaenoic acid, 22:6), 
which range in FO from 0.02 to 6 % [5, 6]. 
 The World Health Organisation (WHO) [7] recommends con-
sumption of fish twice a week, as a preventive measure against 
coronary heart disease and ischaemic stroke. Food and Agriculture 
Organization (FAO) recommends the consumption of 250 mg/day 
of EPA+DHA for adult non-pregnant individuals, but there is no 
consensus on the minimum required dose [8]. In 2012, the Euro-
pean Food Safety Authority (EFSA) concluded that doses up to 
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5 000 mg/day do not impose a health risk for adults [9]. Accumula-
tion of lipophilic environmental pollutants in fish may limit its in-
take [10]. Nevertheless, if moderately consumed, fish and FO exert 
more beneficial than harmful effects and are recommended for nu-
trition [11]. 
 The consumption of fish depends on many factors such as the 
national and personal nutrition habits, geographical position of the 
region (e.g. distance from the sea), gross national product, and the 
price at the local market. The highest consumption of fish in the EU 
is in Portugal (57 kg/person/year) and the lowest in Hungary (5.2 
kg/person/year) [12]. The average fish consumption in the region 
(Serbia, North Macedonia, and Bosnia and Herzegovina) is around 
5.2 kg/person/year, which makes it an area with low usage of this 
food [13].  
 Generally, the synthesis of PUFAs involves two major path-
ways (Fig. 1): 
i) ω-3 pathway - the conversion of α-linolenic acid (ALA, 18:3 
ω-3) to EPA, DPA, and DHA by desaturation, elongation, and 
oxidation reactions [14]. ALA is an essential FA for humans, 
as they cannot synthesise it. Although the conversion of ALA 
to EPA and further to DPA and DHA is possible [15], these 
conversions occur to a very low extent, particularly to DHA 
[14] and they are somewhat greater in women than in men 
[16].  
ii) ω-6 pathway - the conversion of linoleic acid (LA, 18:2 ω-6) 
to arachidonic acid (AA, 20:4 ω-6) by the same reactions as 
mentioned for the ω-3 pathway. 
 Two enzymes, which are responsible for the initial metabolism 
of ω-6 and ω-3 FA, are Δ-5 and Δ-6 desaturase. The first reaction in 
this process is rate-limiting, so the FA which is in excess will react 
first. The optimal ratio of ω-6 to ω-3 FA should be 1-4:1 since both 
desaturases have a higher affinity for ω-3 FA [17]. PUFAs are sub-
1873-4286/19 $58.00+.00  © 2019 Bentham Science Publishers 
1748    Current Pharmaceutical Design, 2019, Vol. 25, No. 15 Šunderić et al. 
strates for different enzymes: cyclooxygenases (to produce prosta-
glandins and thromboxanes), lipoxygenase (to produce leukotrie-
nes), and cytochrome P450 (to produce epoxyeicosatrienoic acids) 
[18].  
 Eicosanoids (prostaglandins, prostacyclin, thromboxanes, leu-
kotrienes) play crucial roles in the vascular physiology due to their 
pro/anti-inflammatory and pro/anti-(platelet) aggregatory effects. 
They control vasodilatation, vasoconstriction, cell growth, prolif-
eration, and immune response [8, 19]. Specialised pro-resolving 
mediators (resolvins, protectins, and maresins) have been identified 
as new ω-3 PUFAs-derived anti-inflammatory mediators, whereas 
ω-6-derived products are considered as pro-inflammatory mediators 
[20]. Plasma and cell levels of ω-6 PUFAs in humans tend to be 
higher than the levels of ω-3 PUFAs due to dietary habits [8]. The 
concentration of ALA in plasma and tissue phospholipids is usually 
less than 0.5 % of the total FA [14]. Mammals lack Δ-15 desatu-
rase, an enzyme which converts ω-6 to ω-3 PUFAs, therefore ω-3 
PUFAs must be supplied in the diet. Although widely present, ω-3 
PUFAs are the most abundant in neurons, retina, and myocardium 
[21]. 
 Cell membrane fluidity, permeability, protein functions, and 
interactions are dependent on the membrane phospholipids whose 
important components are PUFAs. Membrane lipids form specific 
microdomains, the so-called “rafts”, that are essential for the activ-
ity of receptors and enzymes [22]. EPA and DHA modulate the 
formation of “rafts”, especially in the neural, immune, and cancer 
cells [23, 24]. PUFAs participate in and regulate cell signalling 
cascades and gene expression [25]. 
 Since the effects of ω-3 and ω-6 PUFAs and their derivatives 
can be seen as antagonistic, their ratio was suggested to be taken 
into consideration when assessing the inflammatory potential of a 
diet [26]. In modern Western diets, the ω-6/ω-3 ratio is quite high. 
This ratio should not exceed 4:1, but in reality, it varies, being 5.5:1 
in Denmark, 13.8:1 in France, and up to 27:1 in Spain [14]. Plasma 
and cell levels of ω-6 PUFAs tend to be higher than the levels of ω-
3 PUFAs, due to dietary habits, which include high intake of sun-
flower, corn oil, and margarine, and relatively low intake of plant 
seeds and nuts [8]. In Serbian diet, the ω-6/ω-3 ratio is approxi-
mately 10:1. The majority of the population in Serbia (80.3 %) uses 
sunflower oil for daily meal preparation and 18.6 % uses olive oil. 
Sunflower oil contains mostly LA (62.48 %), oleic acid (26.60 %), 
and saturated fatty acids (10.3 %), with no ALA [27].  
 Encapsulated FO is the most common pharmaceutical FO prod-
uct; one form is intended for the preventive application and the 
other for the medically prescribed. Therapeutic application of ω-3 
PUFAs ameliorates severe hyperlipidaemia and atherogenic pa-
rameters, thus lowering the risk of cardiovascular disease (CVD). 
The American Heart Association (AHA) recommends 2-4 g/day of 
EPA and DHA for patients with hyperlipidaemia, but under super-
vision of the physician, as this supplementation may have a nega-
tive influence on the bleeding time, LDL cholesterol, and glycaemic 
control in non-insulin-dependent diabetics [28]. A preventive sup-
plement usually contains 180 mg of EPA and 120 mg of DHA per 1 
000 mg of FO. In a formulation intended for therapy, FAs are found 
in the form of ethyl esters, not triglycerides, which enables their 
better bioavailability, and in greater amounts (on average, three 
times more than in supplements). Besides, therapeutic formulations 
have almost no secondary substances such as pollutants, saturated 
FA, or cholesterol, as standardised by a Current Good Manufactur-
ing Practices document (not applied for the production of supple-
ments) [29].  
3. BENEFICIAL EFFECTS OF FO ON HUMAN HEALTH 
3.1. Cardiovascular Disease (CVD) 
 CVD is the most common cause of human death in the world 
and is associated with an increased concentration of blood lipids. 
 
Fig. (1). The metabolism of ω-6 and ω-3 fatty acids. 
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Atherosclerosis underlies CVD. It develops over time and is more 
likely to be prevented if the management of lipid status starts earlier 
[30]. The main target for this prevention is the reduction of the low-
density lipoprotein particles (LDL) [31].  
 The first observational studies in the 1970s reported that Green-
land Inuit population had a low incidence of coronary artery disease 
(CAD) due to its lifestyle and consumption of the marine fish and 
arctic mammals, both of which are rich in ω-3 PUFAs [32]. A 
number of meta-analyses confirmed beneficial effects of ω-3 PU-
FAs intake on CVD development [33], as regular consumption of 
ω-3 PUFAs may reduce the incidence of fatal myocardial infarction 
by 30 % and overall mortality rate by 20 % if the consumption of 
EPA and DHA were 0.3 to 6 g/day and 0.6 to 3.7 g/day, respec-
tively [34]. In 19 studies, which included 228 864 patients all to-
gether, it was shown that fish consumption reduced the risk of fatal 
coronary heart disease (CHD) by 17 % [35]. In this meta-analysis 
of 19 studies, 8 reported that fish intake was on average 36 g/day. 
Meta-analysis reported by He et al. [36] and Xun et al. [37], re-
vealed that the consumption of fish 2-4 times/week may reduce the 
CHD mortality rate by 23 % compared to the diet without fish or 
with less than one fish meal/month, whereas according to Xun et al. 
[37], the reduction in the stroke rate was 9 %, under the same nutri-
tional regime. Two additional meta-analyses stressed a direct bene-
fit of EPA and/or DHA supplementation on the reduction of CHD 
risk [38, 39]. Meta-study performed by Djoussé et al. [40] con-
firmed that consumption of ω-3 PUFAs from fish lowers the risk of 
heart failure and stroke, whereas a population-based cohort study of 
Mozaffarian et al. [41], showed that boiled or baked fish (but not 
fried) lowers the risk of the incidence of congestive heart failure by 
20 % with an intake 1-2 times/week, 31 % with an intake 3-4 
times/week, and 32 % with an intake greater than 5 times/week. 
The beneficial effect of FO on heart arrhythmia was also shown. 
Consumption of 3.6 g of EPA and DHA for 6 months by the im-
plantable cardioverter defibrillator recipients led to a significant 
reduction of the number of ventricular tachyarrhythmic episodes 
[42]. EPA and DHA administration, 4.2 g/day for the first month 
and 0.85 g/day for the next five months, with EPA to DHA ratio of 
0.9:1.5, was associated with a positive effect on the risk of ar-
rhythmia in patients with idiopathic dilated cardiomyopathy [43]. A 
recent meta-analysis revealed that supplementation with PUFAs, 
with an intake higher than 3.5g/day, leads to a reduction in the heart 
rate compared to PUFAs intake lower than 3.5 g/day [44]. Anti-
arrhythmic effects attributed to ω-3 PUFAs include direct and indi-
rect modulation of the properties of ion channels, membrane com-
position, and fluidity, as well as anti-inflammatory, anti-fibrotic 
effects, and modulation of sympathovagal balance [45]. Omega-3 
PUFAs positively modify the blood lipid profile, thus, lowering the 
risk for development of CVD [46]. A study conducted by Zi-
baeenezhad et al. [47] showed that consumption of fresh fish is 
superior to a prescribed supplementation with ω-3 PUFAs. Partici-
pants in the study were divided into two groups: a dietary fish 
group received 250 g of farmed fish two times/week (they were 
advised not to take any ω-3 PUFAs supplements) and a supplement 
group received 2 g of ω-3 PUFAs every day. Participants from both 
groups consumed a total of 14 g of ω-3 PUFAs per week, for two 
months. A supplementation of ω-3 PUFAs caused a decrease in the 
concentration of triglycerides (TG) and total cholesterol, but there 
was an increase in the concentration of LDL. On the other hand, a 
dietary fish group exhibited improvement in all blood lipid parame-
ters, and to a greater extent compared to the supplement group. The 
main mechanism involved in this effect is the enhancement of beta-
oxidation of FA which reduces the amount of substrate for the for-
mation of very low-density lipoprotein (VLDL) [48]. Different 
effects of DHA and EPA on LDL formation were reported [49], as 
only DHA treatment increased LDL synthesis. Even more, EPA 
treatment led to an 80 % reduction in non-HDL lipoproteins com-
pared to a 40 % reduction due to DHA treatment. DHA was found 
to down-regulate the activity of the LDL receptor [50]. High doses 
of EPA/DHA supplementation (more than 3 g/day) were observed 
to protect endothelium by acting as anti-oxidant and anti-
inflammatory agents [51]. 
 Being a precursor of the family of anti-inflammatory resolvins, 
EPA co-administered with statin therapy induces plaque stabilisa-
tion in patients with the acute CAD [52]. Additionally, ω-3 PUFAs 
administration (3 g/day for 4 weeks) was shown to reduce the levels 
of some coagulation factors, such as factor V and thrombin, by 3.1 
% and 13.9 %, respectively [53]. There is also a large body of evi-
dence that shows a positive effect on lowering blood pressure (BP). 
A meta-analysis conducted by Miller et al. evaluated seventy ran-
domised control trials (RCT) and concluded that supplementation 
of more than 2 g/day of EPA+DHA may reduce both systolic and 
diastolic blood pressure, with the strongest benefits being in hyper-
tensive patients who are not receiving anti-hypertensive medica-
tions [54]. 
 A schematic illustration of the beneficial effects of the con-
sumption of FO is given in Fig. (2).  
3.2. Diabetes Mellitus Type 2  
 Obesity, sedentary lifestyle, and high-energy diets contribute to 
an increase in the number of patients with diabetes mellitus type 2 
(T2DM). In 2015, 415 million people were estimated to have diabe-
tes and the projected increase is up to 642 million by the year 2040 
[55, 56]. T2DM is characterised by impaired insulin secretion, insu-
lin resistance (IR), and vascular complications, resulting in CVD, 
nephropathy, retinopathy, non-alcoholic fatty liver disease 
(NAFLD), and other disturbances [57].  
 Consumption of ω-3 PUFAs was recognised as a dietary and 
therapeutic intervention in the treatment of T2DM. Gonçalves Leão 
Coelho et al. [58] reviewed the impact of ω-3 PUFAs intake on the 
glycaemic control in patients with diabetes and the possible 
mechanisms involved in this process. They have found that sup-
plementation of 0.4-5.2 g/day of ω-3 PUFAs for at least 8 weeks 
improves the glycaemic control in T2DM patients. They suggested 
that mechanisms responsible for the improvement of glycaemic 
control are interconnected with the inflammatory pathways which 
significantly contribute to the insulin resistance (IR). It was pro-
posed that FA stimulate G-protein-coupled receptors (GPR), which 
in turn stimulate insulin secretion. GPR40 (expressed in pancreatic 
β-cells) and GPR120 (expressed in adipose tissue, pro-
inflammatory macrophages, and gastrointestinal tract) in particular, 
are stimulated by ω-3 PUFAs (EPA, DHA), thus affecting insulin 
secretion. Furthermore, when ω-3 PUFAs bind to GPR120, they 
stimulate glucose uptake indirectly, by increasing the expression of 
the glucose transporter GLUT4 in the plasma membrane of muscle 
cells. Another class of receptors, toll-like receptors (TLRs) were 
shown to participate in the T2DM pathogenesis. Increased activa-
tion of TLR2 and TLR4 contributes to inflammation and ω-3 PU-
FAs supplementation was shown to suppress the TLR-induced sig-
nalling pathways and targeted gene expression, exhibiting an anti-
inflammatory effect [58]. 
 Lalia and Lanza [59] summarised the knowledge on the thera-
peutic value of EPA and DHA supplementation and revealed 
encouraging observational evidence both in T2DM patients and in 
non-diabetic people with IR. The strongest effect of the supplemen-
tation was seen in the Alaska Eskimo population [60]. A significant 
improvement in IR and reduction in the level of TNF-α was re-
ported by Rasic-Milutinovic et al. [61] who conducted a study with 
the application of 2.4 g/day of FO for two months, and by Farsi et 
al. [62] who investigated consequences of an intake of 4 g/day of 
FO during 2.5 months. The research of Lepretti et al. [63] stressed 
the connection between IR, endoplasmic reticulum (ER) stress, 
reactive oxygen species (ROS) production, and the impairment of 
the mitochondrial function. They discovered that ω-3 PUFAs stimu-
late mitochondrial function, reduce ROS production, and attenuate 
ER stress, leading to the amelioration of IR. In a PREDIMED study 
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conducted by Sala-Vila et al. [64], which lasted for six years, it was 
shown that the risk of diabetic retinopathy in T2DM patients is 
reduced by 48 % upon regular consumption of ω-3 PUFAs. The 
participants in this study were aimed at meeting a dietary recom-
mendation of at least 0.5 g/day of long-chain ω-3 PUFAs, which 
equals two meals of oily fish a week.  
3.3. Metabolic Syndrome and Non-Alcoholic Fatty Liver Dis-
ease (NAFLD) 
 Metabolic syndrome (MetS), a group of interconnected physio-
logical, biochemical, clinical, and metabolic disturbances, is a seri-
ous risk factor for the development of CVD and T2DM [65, 66]. 
MetS can be also seen as a state of chronic, low-grade inflamma-
tion, accompanied by IR, visceral adiposity, atherogenic dyslipide-
mia, endothelial dysfunction, elevated blood pressure, hypercoagu-
lable state - in other words, a general chronic metabolic stress [67]. 
The effective preventive and therapeutic approaches to deal with 
MetS include changes in the lifestyle: the loss of weight, diet altera-
tion, and exercise. Application of ω-3 PUFAs from FO was re-
ported to decrease body fat and cholesterol levels as well as to sup-
press appetite and reduce inflammation leading to a weight loss 
[68]. A meta-analysis performed by Gao et al. [69] investigated the 
relation between ω-3 PUFAs and insulin sensitivity. It included 17 
individual studies with all together 672 participants and the final 
conclusion was that short-term supplementation with FO increased 
insulin sensitivity in patients with metabolic disorders. The im-
provement in the endothelial function, the enhancement of the fat 
oxidation, and increased energy expenditure were observed upon 
intake of ω-3 PUFAs [68]. The supplementation of ω-3 PUFAs to 
individuals with the obesity-associated MetS caused a decrease in 
their blood TG as well [70]. Beneficial effects of ω-3 PUFAs in 
lowering blood pressure and reducing vascular inflammatory events 
can be seen as cardioprotective. 
 NAFLD is defined as a macrovascular accumulation of fat in 
more than 5 % of hepatocytes, without increased alcohol intake. It 
is considered as a global health problem, especially if it progresses 
into non-alcoholic steatohepatitis (NASH) and further into liver 
cirrhosis [71]. Consumption of ω-3 PUFAs in FO can reduce lipid 
accumulation in the liver, as well as the levels of liver enzymes, it 
can increase insulin sensitivity and may exert an anti-inflammatory 
effect. Taking into account the confirmed positive effects of FO in 
the treatment of CVD, its potential in the treatment of NAFLD is 
encouraging [17, 72].  
 Nobili et al. [17] reviewed the pathogenesis of NAFLD, to-
gether with the molecular and clinical evidence of the beneficial 
effects of the consumption of ω-3 PUFAs in different forms, in 
children, and in adults. They concluded that high doses of ω-3 PU-
FAs (especially DHA) may have a beneficial effect in an early stage 
of NAFLD, by reducing the liver fat content, but there were no 
convincing effects seen in the later progression of a disease, such as 
liver inflammation and fibrosis.  
 In a recently published systematic study and meta-analysis of 
several RCTs, ω-3 PUFAs supplementation was shown to reduce 
the level of alanine aminotransferase (ALT) in blood and to im-
prove the function of liver cells in patients with NAFLD [73]. Two 
meta-analyses, conducted by Yan et al. and Musa-Veloso et al., 
revealed that supplementation of ω-3 PUFAs leads to a reduction in 
liver fat, ALT, aspartate aminotransferase (AST), γ-glutamyl trans-
ferase (GGT), TG, and improved insulin sensitivity [74, 75]. Al-
though there is plenty of evidence that regular consumption of fatty 
fish benefits metabolism, the positive effect in NAFLD treatment is 
not straightforward and there is currently no recommended optimal 
dose for this purpose [17].  
3.4. Cancer 
 Cancer is a widespread pathological state of an organism, char-
acterised by the growth of abnormal cells beyond their usual 
boundaries, which can then invade adjacent parts of the body and/or 
spread to other organs. Globally it is considered to be the second 
leading cause of death, with an estimated 9.6 million deaths in 2018 
[76]. Development of the cancer is under the control of various 
factors (age, genetics, environment, chemical substances, obesity, 
physical activity, lifestyle, etc.). One of the ways to prevent and 
help treat cancer is through the regulation of diet.  
 Application of high-energy, high-fat (Western) diet was corre-
lated with an increased chance of developing cancer, as reviewed 
by Bartsch et al. Although the mechanism of fat-related carcino-
genesis has not been fully understood, studies have associated it 
mainly with a high content of trans-monounsaturated fatty acids 
(C18:1) and a high ω-6: ω-3 ratio (>10:1) of PUFAs. Although 
most of the pre-clinical studies, conducted on animal or cell line 
Fig. (2). Beneficial effects of the consumption of FO on the cardiovascular system. 
Is There Something Fishy About Fish Oil Current Pharmaceutical Design, 2019, Vol. 25, No. 15    1751 
cancer models, reported beneficial effects of ω-3 PUFAs on cancer 
treatment, clinical data should be taken into consideration with 
greater importance [77]. 
 Nutritional habits which include food rich in PUFAs (preferen-
tially ω-3 EPA and DHA) was correlated with a lower incidence of 
cancer in the population consuming fish and FO more than 3 
times/week [78, 79]. This protective effect of PUFAs in parental 
nutrition can be translated to the offspring, similarly as in the case 
of mammary tumors [80]. Also, it is a known fact that cancer pa-
tients have low baseline status of ω-3 PUFAs incorporated in eryth-
rocytes membranes [81, 82]. A better outcome in patients with co-
lorectal (CRC), prostate, gastric, lung, or breast cancer who prac-
ticed these dietary habits was also reported [83-87]. According to 
these data, daily supplementation of 0.2-3 g of PUFA (with the ratio 
EPA: DHA being 1:1) during a period of 1 to 6 weeks improves 
general condition, recovery and the survival rate of patients during 
and after the therapy.  
 Several RCTs have shown these beneficial effects. A study 
performed by Cockbain et al. in 2014 found that supplementation of 
2 g of EPA in CRC patients undergoing liver resection surgery 
reduced the vascularity of CRC liver metastasis and improved over-
all survival compared to controls [88]. Bougnoux et al. showed that 
supplementation of 1.8 g of DHA in metastatic breast cancer pa-
tients led to greater overall survival compared to control group [89], 
while Murphy et al. found that application of 2.5 g of EPA+DHA in 
non-small-cell lung carcinoma patients was followed by an in-
creased response rate and greater clinical benefit. Also, one-year 
survival tended to be greater in the treated group (60%) versus the 
control group (38.7%) [90]. A study of Ma et al. evaluated results 
from 11 prospective cohort RCTs, and showed that supplementation 
of EPA (1-6 g) and /or DHA (0.96-1 g) in inoperable pancreatic 
cancer patients had beneficial effect regarding an increase in body 
weight and lean body mass, as well as overall surviving rate [91].  
 While the exact mechanism of the action of these two FA re-
mains unknown, it was proposed that they are incorporated in the 
membranes of cancer cells, where they participate in increased lipid 
peroxidation, thus targeting cancer cells for the destruction [92]. 
Other processes which accompany this incorporation include modu-
lation of the pathways controlled by cyclooxygenase and lipoxy-
genase, impaired behavior of lipid rafts and disturbances in the 
signaling pathway exerted via GPR.  
 It is known that many anti-neoplastic drugs are non-selective 
towards cancer and healthy cells, so the supplementation of DHA 
and EPA as an adjuvant to standard therapies was shown to reduce 
negative effects of chemotherapy by modulating an immune re-
sponse, manifesting anti-inflammatory effects [93], or by exerting 
other beneficial effects, such as those on gut microbiota in patients 
with colorectal carcinoma [86].  
3.5. Gut Microbiota 
 Human gastrointestinal tract (GIT) harbors a complex and dy-
namic population of microorganisms, counting 10-100 trillion of 
symbiotic microbial cells, which makes roughly 10 times more 
bacterial than human cells in GIT [94]. Microbiota directly com-
municates with the host, as bacterial enzymes produce metabolites 
which are later absorbed by gut enterocytes, thus affecting the 
physiological processes in the host. The emerging evidence on the 
importance of the microbiotic flora in the gut is pointing to its vital 
role both in health and in disease [95]. Alteration in the composi-
tion of the microbiota is known as dysbiosis. It can be caused by the 
pathophysiological state of the host organism and vice versa [96]. 
Dietary habits can significantly affect the composition of the gut 
microbiota, thus regulating the host-microbiota relation [97]. The 
effect of dietary fats was not examined thoroughly, although there 
is growing evidence on their beneficiary impact on the gut microbi-
ota, as reviewed by Constantini et al. [98].  
 Diet supplemented with FO has beneficial effects on the com-
position of the microbiota and ensures healthy ageing and wellbe-
ing. Menni et al. have found a strong correlation between intake of 
ω-3 PUFAs, gut microbiome diversity, and composition in middle-
aged and elderly women [99]. Càndido et al. [100] reported that 
consumption of FO can restore microbiotic composition by affect-
ing short chain FA mainly produced as metabolites of the microbi-
ota, thus influencing energy metabolism and the inflammatory re-
sponse. The authors recommended avoidance of the saturated FA 
and recommended intake of ω-3 PUFAs in order to regulate gut 
microbiota, systematic low-grade inflammation, and to promote 
mechanisms which control body fat and weight.  
 Watson et al. [101] investigated the effect of ω-3 PUFAs on the 
fecal microbiome in middle-aged healthy volunteers. Two different 
formulations of supplements were applied: soft gel capsules and 
Smartfish drinks. The authors found that both formulations induced 
similar changes in the composition of FA in red blood cells and 
promoted a reversible increase in several bacterial genera. How-
ever, only drink formulation was associated with a prolonged de-
crease of AA levels. As can be seen from this study, there is no 
simple relationship between intestinal microbiome and supplemen-
tation of ω-3 PUFAs.  
3.6. Asthma and Allergy 
 Asthma is another prevalent disease, characterised by chronic 
airway inflammation; it affects approximately 300 million individu-
als worldwide [102]. The most common form is atopic asthma 
which is genetically predisposed [103]. In order to reduce the inci-
dence of asthma, researchers investigated the possible anti-
inflammatory therapeutic effect of ω-3 PUFAs on the pathogenesis 
of this disease.  
 The positive effect of their consumption on asthma and other 
allergic diseases was demonstrated by Miyata and Arita [104]. They 
reviewed a large body of evidence and reported that maternal fish 
intake during pregnancy has beneficial effects on allergic or atopic 
outcomes in infants. Nutrition in pregnancy plays an important role 
in the development of the foetus. In the case of asthma, consump-
tion of ω-3 PUFAs can be of particular importance. FO and ω-3 
PUFAs supplementation in late pregnancy was shown to exhibit 
prophylactic potential in the case of asthma in newborns, as shown 
by Olsen et al. [105]. This population-based study, which recruited 
533 women with normal pregnancies, supplemented with 2.7 g of 
ω-3 PUFAs, and 131 pregnant women who received olive oil, dem-
onstrated that children from the ω-3 PUFAs group had a reduction 
in the hazard rate of asthma by 63 %, whereas the hazard rate of the 
allergic asthma was reduced by 87 %, after 16 years follow up. 
Bisgaard et al. [106] found that supplementation with FO in the 
third trimester of pregnancy reduced the risk of wheeze and asthma, 
as well as the incidence of lower respiratory tract infections in new-
borns. This clinical trial included 695 children and three years of 
follow up period. The risk of wheeze or asthma in children was 
reduced for 30.7% in the treatment group compared to the placebo. 
A detailed subgroup analysis revealed that the positive effect was 
the strongest in children whose mothers had blood levels of EPA 
and DHA in the lowest third of the trialled population [106], point-
ing out to the importance of determining the proper baseline status.  
 Omega -3 PUFAs from fish and FO were suggested to alter the 
synthesis of eicosanoid mediators produced from ω-6 PUFAs such 
as AA, responsible for the manifestation of the allergic disease. 
Increased consumption of EPA + DHA results in an elevated pro-
portion of these FAs in the membranes of immune cells, at the ex-
pense of ω-6 PUFAs. As already said, ω-6 PUFAs act as substrates 
for enzymes responsible for the synthesis of prostaglandins, throm-
boxanes, and leukotrienes, all pro-inflammatory molecules. ω-3 
PUFAs can also be substrates for the same enzymes, in which case 
the products of enzymatic reactions are pro-resolving mediators 
such as resolvins (produced from both EPA and DHA) as well as 
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protectins and maresins (produced from DHA). These compounds 
are potent anti-inflammatory mediators. An increased intake of ω-3 
PUFAs acts dually, on one side the production of pro-inflammatory 
AA-derived mediators is decreased, and on the other, the synthesis 
of anti-inflammatory mediators is promoted [25].  
 FO supplementation in healthy babies was shown to signifi-
cantly influence the composition of the erythrocyte FA by increas-
ing ω-3 and decreasing ω-6 PUFAs, contributing to the increased 
production of anti-inflammatory and reduction of pro-inflammatory 
cytokines, and causing faster maturation of the immune system 
[107]. A meta-analysis conducted by Best et al. [108] revealed that 
supplementation of FO in pregnant mothers may result in a reduced 
risk of allergic disease in an offspring.  
3.7. Rheumatoid Arthritis 
 Rheumatoid arthritis (RA) is the most common autoimmune 
disease affecting the synovium and causing chronic inflammation 
of joints, destruction of the cartilage, functional disability, systemic 
complications, and sometimes even death [109]. The main symp-
toms of the disease are joint stiffness, swelling, pain, and loss of 
mobility [110]. RA is more common in women (18 %) than in men 
(9.6%) [111]. Even though it primarily affects the joints of hips, 
knees, and hands [112], it can also have an influence on tissues 
such as ligaments and subchondral bone [113]. Prolonged life ex-
pectancy is one of the main reasons which makes RA one of the 
major factors of disability in the elderly. 
 The etiology of RA lies in the infiltration of elements of the 
immune system in the joint tissues. Activated T cells, macrophages, 
antigen producing B cells and synoviocytes, the fibroblast-like 
synovial cells, invade the synovium, that is, the tissue lining the 
joints. These cells stimulate the production of pro-inflammatory 
molecules, such as prostaglandin E2, tumor necrosis factor (TNF), 
interleukin (IL)-1, and cytokines [114, 115].  
 As already mentioned, ω-3 PUFAs possess strong anti-
inflammatory action and that is why numerous RCT trials showed 
they could ameliorate and improve clinical parameters of RA. Ra-
jaei et al. conducted a 12 week, double-blind, placebo-controlled 
RCT with sixty patients (49 females and 11 males) in the early 
stage of RA, that is the individuals which were diagnosed with the 
disease no more than six months ago. They adhered to earlier 
treatment regimens, by taking the same medication which was pre-
scribed by the doctors. The patients consumed two ω-3 capsules per 
day, which contained 1.8 and 2.1 g of EPA and DHA, respectively. 
Every four weeks for three months, they went for a clinical and 
laboratory evaluation, where, according to the American College of 
Rheumatology (ACR), various parameters were examined. Testing 
was carried out with the help of the disease activity score (DAS-28) 
which contains variables for the number of swollen and painful 
joints, erythrocyte sedimentation rate (ESR), and overall assessment 
of the patient's general health status [116]. Forty-nine patients suc-
cessfully completed the study and results showed improvement in 
many characteristics of patients with active rheumatoid arthritis 
who received diet supplements of ω - 3 along with the standard 
treatment. The overall effect of three months use of ω-3 capsules 
leads to significant reduction of pathologic parameters (mean morn-
ing stiffness decreased in the ω-3 group from 128 minutes to 40 
minutes; the average number of tender joints was reduced from 21 
to 5 joints; the number of swollen joints dropped from 10 to 3; the 
average ESR decreased from 39 to 16 mm/h and pain sensation was 
markedly reduced). There was a 72 % drop of analgesic use among 
the respondents, and of that 32 % completely discontinued the use 
of pain medication and 40% reduced the dose [117]. 
 Similar, a three months study was performed by Veselinovic  
et al. with sixty female patients who were diagnosed with RA in 12-
180 months time period before the beginning of the study. Except 
for the change in clinical parameters, the study wanted to monitor 
the change of plasma phospholipids, which can be considered a 
biomarker of FA used in nutrition. The new FA introduced, γ-
linolenic acid (GLA), which, although ω-6 fatty acid, possesses an 
anti-inflammatory effect. The patients were assigned in three 
groups. The first group received 5 capsules of FO (each capsule 
contained 1g of FO with 300 mg of DHA, 200 mg of EPA, and 100 
mg of other ω - 3 PUFAs) per day. The second group received 2 
capsules of FO and 2 capsules of Evening Primrose Oil (EPO), the 
source of GLA (one gel capsule contains 1300 mg of evening prim-
rose oil with 949 mg of LA and 117 mg of GLA) per day, and the 
third group represented controls. All patients were taking conven-
tional doses of medication prescribed by a physician. The DAS-28 
score system was used. The examination of patients' states was 
made two times, at the beginning of the study (baseline) and at the 
end. 
 Statistically significant reduction in DAS-28 score was ob-
served in groups I and II. The DAS 28 score in group III trended 
towards a significant decrease. The pain sensation in joints was 
statistically reduced in both supplemented groups relative to con-
trols. Due to a higher daily intake of FO, plasma phospholipid con-
tent in group I and II, showed significantly higher levels of EPA, 
DHA, ω-3 PUFA, and total PUFA, relative to baseline values. The 
ω-6/ω-3 ratio was significantly reduced in groups I and II, while in 
group III, there was no change in levels of these FAs in plasma 
phospholipids [118]. 
 Increased systematic inflammation and arterial stiffness are 
hallmarks of the RA. The severity of the arterial stiffness is meas-
ured by an augmentation index. It was recently reported by Wood-
man et al. that patients with RA who consume more ω-3 PUFAs 
and FO have significantly lower augmentation index compared to 
the group with low ω-3 PUFAs intake. Addition of ω-3 PUFAs 
seems to be able to prevent arterial stiffening and possibly slow 
down the progression of arterial ageing [119]. 
 In a recently published meta-analysis, Gioxari et al. [120] found 
that oral intake of ω-3 PUFAs for a minimum of 3 months leads to 
significant improvement in eight markers related to RA. They re-
ported on the leukotriene B4 and TG reduction. It is important to 
note that this analysis was based on 20 RCTs and 1 288 patients 
with RA divided into two subgroups according to their daily intake 
of ω-3 PUFAs (<3 g/day and ≥3 g/day). The other finding was a 
significant amelioration in the global physical assessment, together 
with an increased left and right grip strength after supplementation 
with a high dose of ω-3 PUFAs. 
 Di Giuseppe et al. [121] performed a prospective cohort study 
on women who collected data for ten years via a self-administered 
questionnaire. This examination revealed that intake of dietary ω-3 
PUFAs of more than 0.21 g/day resulted in 35 % decreased risk of 
RA, while an intake higher than 0.21 g/day during a longer period 
of time was associated with 52 % decreased risk. In a review paper 
published by Philippou and Nikiphorou [122], it is suggested that 
increased consumption of fatty fish contributes to lowering the risk 
of RA. However, they also stressed the importance of reduced con-
sumption of sugar and the maintenance of normal body weight, in 
addition to fatty fish consumption.  
4. CONTROVERSIES CONCERNING THE BENEFICIAL 
EFFECTS OF FO AND ω-3 FATTY ACIDS 
 Besides numerous studies which support the opinion that FO 
and ω-3 PUFAs are beneficial for human health, there are also oth-
ers which question their effects. In addition, even some contradic-
tory results were obtained denying the existence of firm statistical 
evidence of the preventative role of PUFAs. 
 Many of the supposed/proved benefits of FO are assigned to the 
effects of ω-3 PUFAs, especially EPA and DHA, but it is worth 
mentioning that not many trials took into account the significant 
amounts of liposoluble vitamins being consumed at the same time 
and did not review and evaluate the associated benefits and risks 
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involved. A recently published investigation examined the relation 
between intake of vitamins A and D during pregnancy, supplemen-
tation with vitamins A and D at infant age, and the risk associated 
with the occurrence of child asthma at 7 years of age [123]. The 
study used data on 61 676 school-age children, the supplement 
intake of their mothers during pregnancy (from various sources), as 
well as the information on the infant intake of supplements at 6 
months, and related them to the occurrence and development of the 
symptoms of asthma. Excessive intake of vitamin A (≥ 2.5 times 
the recommended amount) during pregnancy was associated with 
increased risk, whereas the intake of vitamin D close to the recom-
mended doses was associated with reduced risk of asthma. In addi-
tion, the study concluded that there were no registered antagonistic 
effects of vitamin A and D during high intake of both vitamins, 
therefore opposing the previously supposed antagonistic effects of 
these vitamins claimed by Bastie et al. in 2004 [124]. 
 Vitamin E is also a constituent of FO and its effect on patients 
with CVD was also found to be controversial. Namely, in one 
study, DHA peroxidation and its antiarrhythmic properties in car-
diomyocytes were investigated. It was shown that antioxidant prop-
erties of alpha-tocopherol oppose the antiarrhythmic effects of 
DHA, while in the presence of a pro-oxidant, hydrogen peroxide, 
the beneficial effects of DHA on the prevention of arrhythmia were 
potentiated [125]. 
 In the last two decades, most investigations on FO were dedi-
cated to confirming the potential health benefits of ω-3 PUFAs as 
constituents of FO. However, a number of published results re-
vealed that there is no statistically sufficient evidence to support the 
preventative effect of ω-3 PUFAs, especially in CVD. For example, 
He et al. in 2002 [126] found no significant association between 
fish or long-chain ω-3 PUFAs intake and the risk of hemorrhagic 
stroke, in a large prospective study that included 43 671 men exam-
ined in 1986, 1990, and 1994. The authors concluded that eating 
fish once a month or more can reduce the risk of ischemic stroke, 
but opened the question whether high fish (ω-3 PUFAs) intake con-
tributes to a higher risk of hemorrhagic stroke, due to the influence 
of EPA on platelet aggregation [126, 127].  
 In a cohort study on 41 836 postmenopausal women (55-69 
years old), there was no firm evidence that fish and marine ω-3 
PUFAs prevent CHD or stroke, or that they can be associated with a 
mortality rate from the stroke [128]. Similarly, Jarvinen et al. in 
2006 followed up 2 775 men and 2 445 women (30-79 years of age) 
and concluded that fish consumption in the Finnish population, is 
not offering protection against the development of CHD in men, but 
it may have a protective effect in women [129]. The latest report of 
the Zutphen study, published by Streppel et al. in 2008, concluded 
that the association between long-term fish consumption and death 
from CHD decreases with increasing age. The collected data sug-
gested a reduction in the rate of the sudden coronary death due to 
long-term consumption of fatty fish, but a clear dose–response rela-
tionship between EPA or DHA intake and (sudden) coronary death 
was not established [130]. Similar observations were published by 
de Goede et al. who followed up a group of Dutch people, 22 654 
men and women (20-65 years of age) during 9-14 years. A preven-
tative role of higher doses of EPA, DHA, and fish consumption in 
fatal CHD was confirmed and related to generally high intake of 
fish in a diet. However, they did not confirm that this diet can pro-
tect against non-fatal myocardial infarction [131].  
 In a recent prospective cohort study, conducted by Rhee et al. 
in 2017, a longitudinal examination of the incident major CVD in 
women without previous history of cardiovascular events (39 876 
women over 45 years of age) in relation to the consumption of ω-3 
PUFAs from different sources was performed. It was concluded 
that ALA and marine ω-3 PUFAs intake was not associated with 
major CVD or individual cardiovascular outcomes regardless of the 
age, BMI or the baseline history of hypertension in women, again 
questioning the “power” of ω-3 PUFAs [132].  
 The question whether FO and its constituents are beneficial to 
the health and in what extent, continues to raise controversies, since 
many of the examined and published results addressed different 
populations, different research hypothesis, using different statistical 
approaches, etc. This inconsistency was recognized and several 
authors attempted to explain the controversial results. For example, 
Harris [133] offered a critical review on a number of intervention 
studies and meta-analyses that examined the effects of ω-3 PUFAs. 
Harris reviewed the OMEGA trial conducted in Germany (a coun-
try with low fish intake), which encompassed 3804 CVD patients 
randomized to either 840mg EPA + DHA or placebo [134]. No 
difference between groups was observed, considering trial out-
comes (sudden cardiac death within 1 year and total mortality and 
nonfatal cardiac events). This study was shown to be underpowered 
and too short, and it turned out that about 45% of study participants 
reported consuming fish ‘several times a week’. ORIGIN trial, 
which addressed the efficiency of ω-3 PUFAs (study No. 
NCT00069784), in 12 536 patients at high risk of CVD, diagnosed 
with impaired glucose metabolism, was also reviewed. Supplemen-
tation of 850 mg/day of EPA + DHA was not able to reduce the rate 
of cardiovascular events in high-risk patients and the incidence of 
death due to CVD [135]. Although this study had enough power 
and longest trial period, the absence of positive effects can be at-
tributed to extensive background intake of EPA + DHA.  
 The consequence of baseline dietary behavior in both studies 
(OMEGA and ORIGIN) led to an increase in baseline tissue levels 
of ω -3 fatty acids, where additional supplementation of 1 g or less 
resulted in no improvement at all, as Harris explains. Effects of FO 
supplementation, thus, largely, depend on the plasma/tissue status 
before the intervention [133].  
  A meta-analysis conducted by Aung et al. on 10 trials involv-
ing 77 917 participants [136] summarised several findings conclud-
ing that the supplementation of ω-3 PUFAs for several years (a 
mean of 4.4 years) had no significant benefit on the reduction of 
either fatal, non-fatal CHD rate or other major vascular events.  
 An influence of ω-3 PUFAs intake on insulin sensitivity was 
investigated in a meta-analysis described by Gao et al. which in-
cluded 17 studies and 672 participants. One of the main conclusions 
was that short-term supplementation with FO is associated with 
increased insulin sensitivity in people with metabolic disorders 
[69]. A recent meta-analysis published by Chen et al. [137] stressed 
the population differences in respect to the development of T2DM 
in relation to ω-3 PUFAs supplementation (either EPA or DHA). 
They concluded that consumption of these FA reduced the risk of 
T2DM in the Asian population, whereas the risk was increased in a 
dose-dependent manner in the Western population. 
 There is another controversy in the application of ω-3 PUFAs 
for therapeutic purposes, as not all ω-3 PUFAs are equally applica-
ble or recommended. Deanen et al. [138] conducted a clinical study 
examining the effects of the application of different FA, which can 
be found in the commercial FO formulations, during cancer treat-
ment. They found that one of these FA, 16:4 (ω-3) (hexadeca-
4,7,10,13-tetraenoic acid) ω-3 FA, present in several commercial 
preparations, hampered tumor-directed cytotoxicity of platinum 
compounds at concentrations which are commonly reached in the 
blood of patients who take FO supplements. 
 Although dietary ω-3 PUFAs were suggested as potential sup-
plements in the prevention and suppression of colorectal carcinoma 
(CRC), Weylandt et al. [139] reported no anti-proliferative, no pro-
apoptotic and no anti-inflammatory effect of these PUFAs in CRC. 
Even more, the same authors suggested the potential causal connec-
tion between FO intake and the incidence of CRC in the high-risk 
groups.  
 Studies performed by Chua et al. and Haas-Haseman et al. re-
ported no or even negative correlation between the use of PUFAs 
and the incidence of cancer in a certain population. According to 
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data from the WHO and the FAO, predicted incidence of cancer for 
the population of island Maldives, with the highest fish consump-
tion per capita in the world (185 kg in 2013) or Iceland (92 kg) is 
equal or even higher compared to the similar island population of 
Madagascar, with low consumption of fish (just 4.6 kg) [140, 141]. 
This data imply that investigations need to be more population-
adjusted, in order to see more clearly the effect of PUFAs on the 
development and treatment of cancer. 
 Stark et al. [142] performed a global survey of the blood con-
centrations of DHA and EPA in healthy adults and presented a geo-
graphical distribution of their levels. As expected, the levels differ 
in different populations as a result of different diets. Inhabitants of 
Japan, Scandinavia, and from areas where fish is often consumed 
had the highest concentrations of EPA and DHA. On the other 
hand, very low levels of these acids (≤ 4 %) were measured in the 
populations from North, Central, and South America, Europe, the 
Middle East, Southeast Asia, and Africa. Indeed, Nakamura et al. 
investigated the hypothesis that a high fish intake contributes to 
longevity in Japanese people. In a 19-year lasting follow up of 3 
945 men and 4 934 women, they did not find enough statistical 
evidence to support this hypothesis and reasoned that the absence of 
the effect was due to the generally high consummation of fish in the 
regular Japanese diet [143].  
 As already mentioned, different baseline levels of ω-3 PUFAs 
are variables which need to be taken into consideration when dis-
cussing the effects of supplementation. 
 In a recent review, Roy et al. [125] suggested raising an inter-
national initiative to standardize the approach in conducting trials 
related to EPA and DHA health benefits. They proposed to take 
into account the dose, the type of FA supplemented and to include a 
“PUFA index” in evaluation, referring to the index proposed by von 
Schacky in 2010, which expresses the percentage of EPA+DHA in 
total lipids in red blood cells [144]. These authors also stressed the 
importance of defining a baseline standard for FA concentrations in 
order to overcome multi-factorial impacts, such as different eating 
habits of different populations.  
 Moreover, the effects of ω -3 PUFAs depend on its source; 
whether it is fish, FO, or a pharmaceutical supplement. For in-
stance, the supplements mostly contain no vitamins, only negligible 
concentrations of vitamin E (added as an antioxidant). When con-
suming fish, not only FO is ingested, but also proteins and trace 
minerals, lipophilic polyphenols which are lost during the FO ex-
traction, and encapsulation. These elements could be the very thing 
that contributes to the health benefits of fish as food. They protect 
the ω -3 PUFAs from oxidation and possess health benefits by 
themselves [145]. FO is considered a supplement (not counting the 
prescription form) and as such does not comply with the strict 
pharmaceutical regulations. There are a number of cases where the 
real content of ω-3 PUFAs in capsules was lower than it was writ-
ten on the label, and the amount of oxidized forms were above rec-
ommended limits [146]. On the other hand, capsules are more con-
venient to consume and devoided of mercury or chemical contami-
nants found in fish [147]. 
CONCLUSION 
 In conclusion, it is known that long-chain ω -3 PUFAs as con-
stituents of FO can contribute more to prevent a disease than to 
manifest a therapeutic outcome. A deficiency arising from long-
chain ω-3 PUFAs is not registered in a regular diet, so the real ef-
fect remains practically unknown so far. Furthermore, increased 
knowledge of the beneficial effects of ω -3 PUFAs has inevitably 
led to an increase in the consummation of food and supplements 
that contain them.  
 Although the effects of FO are being investigated for many 
decades and many results exist, this article gives a brief summary of 
the examined effects of the constituents of FO, especially in CVD, 
T2DM, cancer, asthma and allergy, NAFLD, RA, and on the gut 
microbiota. In addition, we tried to summarize the reported contro-
versies regarding some claimed health benefits. 
 It is to be expected that controversial reports will continue to 
emerge, since many of the examined and published results so far 
addressed different populations and different research hypothesis, 
using different statistical approaches, and standardization may re-
duce the influence of specific variables to some extent.  
CONSENT FOR PUBLICATION 
 Not applicable. 
FUNDING
 None.
CONFLICT OF INTEREST 
 The authors declare no conflict of interest, financial or other-
wise.  
ACKNOWLEDGEMENTS 
 This work was performed as part of the activities within COST 
Action CA 16112 - Personalized Nutrition in an aging society: re-
dox control of major age-related diseases (NutRedOx). 
REFERENCES 
[1] Weichselbaum E, Coe S, Buttriss J, Stanner S. Fish in the diet: A 
review. Nutr Bull 2013; 38: 128-77. 
 [http://dx.doi.org/10.1111/nbu.12021] 
[2] Lamberg-Allardt C. Vitamin D in foods and as supplements. Prog 
Biophys Mol Biol 2006; 92(1): 33-8. 
 [http://dx.doi.org/10.1016/j.pbiomolbio.2006.02.017] [PMID: 
16618499] 
[3] SACN (Scientific Advisory Committee on Nutrition). 2004. Advice 
on fish consumption: Benefits & Risks. Office, T.S.: London. 
[4] Shahidi F. Functional seafood lipids and proteins.Functional Foods: 
Biochemical and Processing Aspects. Lancaster, UK: Technomic 
Publ. 1998; pp. 381-401. 
[5] Shahidi F, Ambigaipalan P. Omega-3 polyunsaturated fatty acids 
and their health benefits. Annu Rev Food Sci Technol 2018; 9: 
345-81. 
 [http://dx.doi.org/10.1146/annurev-food-111317-095850] [PMID: 
29350557] 
[6] Strobel C, Jahreis G, Kuhnt K. Survey of n-3 and n-6 polyunsatu-
rated fatty acids in fish and fish products. Lipids Health Dis 2012; 
11: 144. 
 [http://dx.doi.org/10.1186/1476-511X-11-144] [PMID: 23110317] 
[7] WHO (World Health Organisation), Population nutrient intake 
goals for preventing diet-related chronic diseases. [updated 2018; 
cited 2018 Oct 28]. Available from: (www.who.int/nutrition/ top-
ics/5_population_nutrient/en/index13.html)  
[8] Fats and fatty acids in human nutrition Report of an expert consul-
tation. Rome: WHO 2010. 
[9] EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); 
Scientific Opinion related to the Tolerable Upper Intake Level of 
eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and 
docosapentaenoic acid (DPA). EFSA J 2012; 10(7): 2815. [48 pp.] 
doi:10.2903/j.efsa.2012.2815. 
[10] Fernandes A, Smith F, Petch R, et al. Investigation into the Levels 
of Environmental Contaminants in Scottish Marine and Freshwater 
Fin Fish and Shellfish. York: Food and Environment Research 
Agency 
2009.www.food.gov.uk/sites/default/files/media/document/572-1-
1005_S14040-
S14041__Environmental_Contaminants_in_Scottish_Marine_and_
_Freshwater_Fish.pdf [updated 2018; cited 2018 Dec 1] 
[11] FAO/WHO. 2011.  Report of the Joint FAO/WHO Expert Consul-
tation on the Risks and Benefits of Fish Consumption. Rome and 
Geneva. 
[12] EUMOFA 2018. The EU Fish Market.  HIGHLGHTS. THE EU IN 
THE WORLD. EU MARKET SUPPLY. CONSUMPTION. 
Is There Something Fishy About Fish Oil Current Pharmaceutical Design, 2019, Vol. 25, No. 15    1755 
TRADE. EU LANDINGS. AQUACULTURE PRODUCTION. 
[updated 2019; cited 2019 Apr 26]. Available from: 
(http://www.eumofa.eu/) 
[13] FAOSTAT, FAO. Food Balance Sheets: Fish, Seafood - Food 
supply quantity (kg/capita/yr) [updated 2019; cited 2019 Apr 26]. 
Available from:  (www.fao.org/faostat/en/?#data/) 
[14] Burdge GC, Calder PC. Dietary alpha-linolenic acid and health-
related outcomes: A metabolic perspective. Nutr Res Rev 2006; 
19(1): 26-52. 
 [http://dx.doi.org/10.1079/NRR2005113] [PMID: 19079874] 
[15] Calder PC. Very long chain omega-3 (n-3) fatty acids and human 
health. Eur J Lipid Sci Technol 2014; 116(10): 1280-300. 
 [http://dx.doi.org/10.1002/ejlt.201400025] 
[16] Welch AA, Shakya-Shrestha S, Lentjes MA, Wareham NJ, Khaw 
KT. Dietary intake and status of n-3 polyunsaturated fatty acids in a 
population of fish-eating and non-fish-eating meat-eaters, vegetari-
ans, and vegans and the product-precursor ratio [corrected] of α-
linolenic acid to long-chain n-3 polyunsaturated fatty acids: Results 
from the EPIC-Norfolk cohort. Am J Clin Nutr 2010; 92(5): 1040-
51. 
 [http://dx.doi.org/10.3945/ajcn.2010.29457] [PMID: 20861171] 
[17] Nobili V, Alisi A, Musso G, Scorletti E, Calder PC, Byrne CD. 
Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects 
in pediatric and adult NAFLD. Crit Rev Clin Lab Sci 2016; 53(2): 
106-20. 
 [http://dx.doi.org/10.3109/10408363.2015.1092106] [PMID: 
26463349] 
[18] Scaioli E, Liverani E, Belluzzi A. The imbalance between n-6/n-3 
polyunsaturated fatty acids and inflammatory bowel disease: A 
comprehensive review and future therapeutic perspectives. Int J 
Mol Sci 2017; 18(12): E2619. 
 [http://dx.doi.org/10.3390/ijms18122619] [PMID: 29206211] 
[19] Shahidi F, Miraliakbari H. Omega-3 (n-3) fatty acids in health and 
disease: Part 1--cardiovascular disease and cancer. J Med Food 
2004; 7(4): 387-401. 
 [http://dx.doi.org/10.1089/jmf.2004.7.387] [PMID: 15671680] 
[20] Serhan CN. Pro-resolving lipid mediators are leads for resolution 
physiology. Nature 2014; 510: 92-101.  
[21] Schuchardt JP, Hahn A. Bioavailability of long-chain omega-3 
fatty acids. Prostaglandins Leukot Essent Fatty Acids 2013; 89: 1-
8. 
[22] Pike LJ. Lipid rafts: Bringing order to chaos. J Lipid Res 2003; 
44(4): 655-67. 
 [http://dx.doi.org/10.1194/jlr.R200021-JLR200] [PMID: 
12562849] 
[23] Yaqoob P. The nutritional significance of lipid rafts. Annu Rev 
Nutr 2009; 29: 257-82. 
 [http://dx.doi.org/10.1146/annurev-nutr-080508-141205] [PMID: 
19400697] 
[24] Hou TY, McMurray DN, Chapkin RS. Omega-3 fatty acids, lipid 
rafts, and T cell signaling. Eur J Pharmacol 2016; 785: 2-9. 
 [http://dx.doi.org/10.1016/j.ejphar.2015.03.091] [PMID: 
26001374] 
[25] Miles EA, Calder PC. Can early omega-3 fatty acid exposure re-
duce risk of childhood allergic disease? Nutrients 2017; 9(7): 784. 
 [http://dx.doi.org/10.3390/nu9070784] [PMID: 28754005] 
[26] Calder PC. Marine omega-3 fatty acids and inflammatory proc-
esses: Effects, mechanisms and clinical relevance. Biochim Bio-
phys Acta 2015; 1851(4): 469-84. 
 [http://dx.doi.org/10.1016/j.bbalip.2014.08.010] [PMID: 
25149823] 
[27] Vučić V. The Role of dietary polyunsaturated fatty acids in in-
flammation. Serb J Exp Clin Res 2013; 14: 93-9. 
 [http://dx.doi.org/10.5937/sjecr14-4774] 
[28] U. S. Food and Drug Administration. Center for Food Safety and 
Applied Nutrition. Office of Nutritional Products, Labeling, and 
Dietary Supplements. 2000. Letter Regarding Dietary Supplement 
Health Claim for Omega-3 Fatty Acids and Coronary Heart Dis-
ease.  
[29] Brunton S, Collins N. Differentiating prescription omega-3-acid 
ethyl esters (P-OM3) from dietary-supplement omega-3 fatty acids. 
Curr Med Res Opin 2007; 23(5): 1139-45. 
 [http://dx.doi.org/10.1185/030079907X188017] [PMID: 17519081] 
[30] Rosin S, Ojansivu I, Kopu A, Keto-Tokoi M, Gylling H. Optimal 
use of plant stanol ester in the management of hypercholes-
terolemia. Cholesterol 2015; 2015: 706970. 
 [http://dx.doi.org/10.1155/2015/706970] [PMID: 26543642] 
[31] Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of 
more intensive lowering of LDL cholesterol: A meta-analysis of 
data from 170,000 participants in 26 randomised trials. Lancet 
2010; 376(9753): 1670-81. 
 [http://dx.doi.org/10.1016/S0140-6736(10)61350-5] [PMID: 
21067804] 
[32] Bang HO, Dyerberg J, Nielsen AB. Plasma lipid and lipoprotein 
pattern in Greenlandic West-coast Eskimos. Lancet 1971; 1(7710): 
1143-5. 
 [http://dx.doi.org/10.1016/S0140-6736(71)91658-8] [PMID: 
4102857] 
[33] Mori TA. Marine OMEGA-3 fatty acids in the prevention of car-
diovascular disease. Fitoterapia 2017; 123: 51-8. 
 [http://dx.doi.org/10.1016/j.fitote.2017.09.015] [PMID: 28964873] 
[34] Bucher HC, Hengstler P, Schindler C, Meier G. N-3 polyunsatu-
rated fatty acids in coronary heart disease: A meta-analysis of ran-
domized controlled trials. Am J Med 2002; 112(4): 298-304. 
 [http://dx.doi.org/10.1016/S0002-9343(01)01114-7] [PMID: 
11893369] 
[35] Whelton SP, He J, Whelton PK, Muntner P. Meta-analysis of ob-
servational studies on fish intake and coronary heart disease. Am J 
Cardiol 2004; 93(9): 1119-23. 
 [http://dx.doi.org/10.1016/j.amjcard.2004.01.038] [PMID: 
15110203] 
[36] He K, Song Y, Daviglus ML, et al. Accumulated evidence on fish 
consumption and coronary heart disease mortality: A meta-analysis 
of cohort studies. Circulation 2004; 109(22): 2705-11. 
 [http://dx.doi.org/10.1161/01.CIR.0000132503.19410.6B] [PMID: 
15184295] 
[37] Xun P, Qin B, Song Y, et al. Fish consumption and risk of stroke 
and its subtypes: Accumulative evidence from a meta-analysis of 
prospective cohort studies. Eur J Clin Nutr 2012; 66(11): 1199-207. 
 [http://dx.doi.org/10.1038/ejcn.2012.133] [PMID: 23031847] 
[38] Alexander DD, Miller PE, Van Elswyk ME, Kuratko CN, Bylsma 
LC. Eicosapentaenoic and docosahexaenoic long-chain omega-3 
fatty acids and coronary heart disease risk. Mayo Clin Proc 2017; 
92(1): 15-29. 
 [http://dx.doi.org/10.1016/j.mayocp.2016.10.018] [PMID: 
28062061] 
[39] Maki KC, Palacios OM, Bell M, Toth PP. Use of supplemental 
long-chain omega-3 fatty acids and risk for cardiac death: An up-
dated meta-analysis and review of research gaps. J Clin Lipidol 
2017; 11(5): 1152-1160.e2. 
 [http://dx.doi.org/10.1016/j.jacl.2017.07.010] [PMID: 28818347] 
[40] Djoussé L, Akinkuolie AO, Wu JH, Ding EL, Gaziano JM. Fish 
consumption, omega-3 fatty acids and risk of heart failure: A meta-
analysis. Clin Nutr 2012; 31(6): 846-53. 
 [http://dx.doi.org/10.1016/j.clnu.2012.05.010] [PMID: 22682084] 
[41] Mozaffarian D, Bryson CL, Lemaitre RN, Burke GL, Siscovick 
DS. Fish intake and risk of incident heart failure. J Am Coll Cardiol 
2005; 45(12): 2015-21. 
 [http://dx.doi.org/10.1016/j.jacc.2005.03.038] [PMID: 15963403] 
[42] Weisman D, Beinart R, Erez A, et al. Effect of supplemented in-
take of omega-3 fatty acids on arrhythmias in patients with ICD: 
Fish oil therapy may reduce ventricular arrhythmia. J Interv Card 
Electrophysiol 2017; 49(3): 255-61. 
 [http://dx.doi.org/10.1007/s10840-017-0267-1] [PMID: 28664342] 
[43] Nodari S, Metra M, Milesi G, et al. The role of n-3 PUFAs in pre-
venting the arrhythmic risk in patients with idiopathic dilated car-
diomyopathy. Cardiovasc Drugs Ther 2009; 23(1): 5-15. 
 [http://dx.doi.org/10.1007/s10557-008-6142-7] [PMID: 18982439] 
[44] Hidayat K, Yang J, Zhang Z, et al. Effect of omega-3 long-chain 
polyunsaturated fatty acid supplementation on heart rate: A meta-
analysis of randomized controlled trials. Eur J Clin Nutr 2018; 
72(6): 805-17. 
 [http://dx.doi.org/10.1038/s41430-017-0052-3] [PMID: 29284786] 
[45] Tribulova N, Szeiffova Bacova B, Egan Benova T, Knezl V, 
Barancik M, Slezak J. Omega-3 index and anti-arrhythmic potential 
of omega-3 PUFAs. Nutrients 2017; 9(11): 1191. 
1756    Current Pharmaceutical Design, 2019, Vol. 25, No. 15 Šunderić et al. 
 [http://dx.doi.org/10.3390/nu9111191] [PMID: 29084142] 
[46] Burke MF, Burke FM, Soffer DE. Review of cardiometabolic ef-
fects of prescription omega-3 fatty acids. Curr Atheroscler Rep 
2017; 19(12): 60. 
 [http://dx.doi.org/10.1007/s11883-017-0700-z] [PMID: 29116404] 
[47] Zibaeenezhad MJ, Ghavipisheh M, Attar A, Aslani A. Comparison 
of the effect of omega-3 supplements and fresh fish on lipid profile: 
A randomized, open-labeled trial. Nutr Diabetes 2017; 7(12): 1. 
 [http://dx.doi.org/10.1038/s41387-017-0007-8] [PMID: 29259181] 
[48] Backes J, Anzalone D, Hilleman D, Catini J. The clinical relevance 
of omega-3 fatty acids in the management of hypertriglyceridemia. 
Lipids Health Dis 2016; 15(1): 118. 
 [http://dx.doi.org/10.1186/s12944-016-0286-4] [PMID: 27444154] 
[49] Jacobson TA, Glickstein SB, Rowe JD, Soni PN. Effects of eicos-
apentaenoic acid and docosahexaenoic acid on low-density lipopro-
tein cholesterol and other lipids: A review. J Clin Lipidol 2012; 
6(1): 5-18. 
 [http://dx.doi.org/10.1016/j.jacl.2011.10.018] [PMID: 22264569] 
[50] Fialkow J. Omega-3 fatty acid formulations in cardiovascular dis-
ease: Dietary supplements are not substitutes for prescription prod-
ucts. Am J Cardiovasc Drugs 2016; 16(4): 229-39. 
 [http://dx.doi.org/10.1007/s40256-016-0170-7] [PMID: 27138439] 
[51] Nastel P, Shige H, Pomeroy S, Cehun M, Abbey M, Raederstorff 
D. The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic 
acid increase systemic arterial compliance in humans. Am J Clin 
Nutr 2002; 76: 326-30.  
[52] Yamano T, Kubo T, Shiono Y, et al. Impact of eicosapentaenoic 
acid treatment on the fibrous cap thickness in patients with coro-
nary atherosclerotic plaque: An optical coherence tomography 
study. J Atheroscler Thromb 2015; 22(1): 52-61. 
 [http://dx.doi.org/10.5551/jat.25593] [PMID: 25132379] 
[53] Vanschoonbeek K, Feijge MAH, Paquay M, et al. Variable hypo-
coagulant effect of fish oil intake in humans: Modulation of fi-
brinogen level and thrombin generation. Arterioscler Thromb Vasc 
Biol 2004; 24(9): 1734-40. 
 [http://dx.doi.org/10.1161/01.ATV.0000137119.28893.0b] [PMID: 
15217806] 
[54] Miller PE, Van Elswyk M, Alexander DD. Long-chain omega-3 
fatty acids eicosapentaenoic acid and docosahexaenoic acid and 
blood pressure: A meta-analysis of randomized controlled trials. 
Am J Hypertens 2014; 27(7): 885-96. 
 [http://dx.doi.org/10.1093/ajh/hpu024] [PMID: 24610882] 
[55] Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet 2017; 
389(10085): 2239-51. 
 [http://dx.doi.org/10.1016/S0140-6736(17)30058-2] [PMID: 
28190580] 
[56] De Fronzo RA, Ferrannini E, Groop L, et al. Type 2 diabetes melli-
tus. Nat Rev/ Dis Primers 2015; 1: 15019. 
[57] Itsiopoulos C, Marx W, Mayr HL, et al. The role of omega-3 poly-
unsaturated fatty acid supplementation in the management of type 2 
diabetes mellitus: A narrative review. J Nutr Intermed Metab 2018; 
14: 42-51. 
 [http://dx.doi.org/10.1016/j.jnim.2018.02.002] 
[58] Coelho OGL, da Silva BP, Rocha DMUP, Lopes LL, Alfenas 
RCG. Polyunsaturated fatty acids and type 2 diabetes: Impact on 
the glycemic control mechanism. Crit Rev Food Sci Nutr 2017; 
57(17): 3614-9. 
 [http://dx.doi.org/10.1080/10408398.2015.1130016] [PMID: 
26853892] 
[59] Lalia AZ, Lanza IR. Insulin-Sensitizing Effects of Omega-3 Fatty 
Acids: Lost in Translation? Nutrients 2016; 8(6): 329-53. 
 [http://dx.doi.org/10.3390/nu8060329] [PMID: 27258299] 
[60] Ebbesson SO, Risica PM, Ebbesson LO, Kennish JM, Tejero ME. 
Omega-3 fatty acids improve glucose tolerance and components of 
the metabolic syndrome in Alaskan Eskimos: The Alaska Siberia 
project. Int J Circumpolar Health 2005; 64(4): 396-408. 
 [http://dx.doi.org/10.3402/ijch.v64i4.18016] [PMID: 16277123] 
[61] Rasic-Milutinovic Z, Perunicic G, Pljesa S, et al. Effects of N-3 
PUFAs supplementation on insulin resistance and inflammatory 
biomarkers in hemodialysis patients. Ren Fail 2007; 29(3): 321-9. 
 [http://dx.doi.org/10.1080/08860220601184092] [PMID: 
17497447] 
[62] Farsi PF, Djazayery A, Eshraghian MR, et al. Effects of supple-
mentation with omega-3 on insulin sensitivity and non-esterified 
free fatty acid (NEFA) in type 2 diabetic patients. Arq Bras Endo-
crinol Metabol 2014; 58(4): 335-40. 
 [http://dx.doi.org/10.1590/0004-2730000002861] [PMID: 
24936727] 
[63] Lepretti M, Martucciello S, Burgos Aceves MA, Putti R, Lionetti 
L. Omega-3 Fatty Acids and Insulin Resistance: Focus on the 
Regulation of Mitochondria and Endoplasmic Reticulum Stress. 
Nutrients 2018; 10(3): 349-59. 
 [http://dx.doi.org/10.3390/nu10030350] [PMID: 29538286] 
[64] Sala-Vila A, Díaz-López A, Valls-Pedret C, et al. Dietary Marine 
ω-3 Fatty Acids and Incident Sight-Threatening Retinopathy in 
Middle-Aged and Older Individuals With Type 2 Diabetes: Pro-
spective Investigation From the PREDIMED Trial. JAMA Oph-
thalmol 2016; 134(10): 1142-9. 
 [http://dx.doi.org/10.1001/jamaophthalmol.2016.2906] [PMID: 
27541690] 
[65] Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis andmanage-
ment of the metabolic syndrome: An American Heart Associa-
tion/NationalHeart, Lung, and Blood Institute scientific statement. 
Circulation 2005; 112(17): 2735-52. 
 [http://dx.doi.org/10.1161/CIRCULATIONAHA.105.169404] 
[PMID: 16157765] 
[66] Wilson PWF, D’Agostino RB, Parise H, Sullivan L, Meigs JB. 
Metabolic syndrome as a precursor of cardiovascular disease and 
type 2 diabetes mellitus. Circulation 2005; 112(20): 3066-72. 
 [http://dx.doi.org/10.1161/CIRCULATIONAHA.105.539528] 
[PMID: 16275870] 
[67] Kaur J. A comprehensive review on metabolic syndrome. Cardiol 
Res Pract 2014; 2014: 943162. 
 [http://dx.doi.org/10.1155/2014/943162] [PMID: 24711954] 
[68] Torres-Fuentes C, Schellekens H, Dinan TG, Cryan JF. A natural 
solution for obesity: Bioactives for the prevention and treatment of 
weight gain. A review. Nutr Neurosci 2015; 18(2): 49-65. 
 [http://dx.doi.org/10.1179/1476830513Y.0000000099] [PMID: 
24621068] 
[69] Gao H, Geng T, Huang T, Zhao Q. Fish oil supplementation and 
insulin sensitivity: A systematic review and meta-analysis. Lipids 
Health Dis 2017; 16(1): 131. 
 [http://dx.doi.org/10.1186/s12944-017-0528-0] [PMID: 28673352] 
[70] Lorente-Cebrián S, Costa AGV, Navas-Carretero S, Zabala M, 
Martínez JA, Moreno-Aliaga MJ. Role of omega-3 fatty acids in 
obesity, metabolic syndrome, and cardiovascular diseases: A re-
view of the evidence. J Physiol Biochem 2013; 69(3): 633-51. 
 [http://dx.doi.org/10.1007/s13105-013-0265-4] [PMID: 23794360] 
[71] Torres DM, Williams CD, Harrison SA. Features, diagnosis, and 
treatment of nonalcoholic fatty liver disease. Clin Gastroenterol 
Hepatol 2012; 10(8): 837-58. 
 [http://dx.doi.org/10.1016/j.cgh.2012.03.011] [PMID: 22446927] 
[72] Gupta V, Mah XJ, Garcia MC, Antonypillai C, van der Poorten D. 
Oily fish, coffee and walnuts: Dietary treatment for nonalcoholic 
fatty liver disease. World J Gastroenterol 2015; 21(37): 10621-35. 
 [http://dx.doi.org/10.3748/wjg.v21.i37.10621] [PMID: 26457022] 
[73] Yu L, Yuan M, Wang L. The effect of omega-3 unsaturated fatty 
acids on non-alcoholic fatty liver disease: A systematic review and 
meta-analysis of RCTs. Pak J Med Sci 2017; 33(4): 1022-8. 
 [http://dx.doi.org/10.12669/pjms.334.12315] [PMID: 29067086] 
[74] Yan J-H, Guan B-J, Gao H-Y, Peng XE. Omega-3 polyunsaturated 
fatty acid supplementation and non-alcoholic fatty liver disease: A 
meta-analysis of randomized controlled trials. Medicine (Balti-
more) 2018; 97(37): E12271. 
 [http://dx.doi.org/10.1097/MD.0000000000012271] [PMID: 
30212963] 
[75] Musa-Veloso K, Venditti C, Lee HY, et al. Systematic review and 
meta-analysis of controlled intervention studies on the effective-
ness of long-chain omega-3 fatty acids in patients with nonalco-
holic fatty liver disease. Nutr Rev 2018; 76(8): 581-602. 
 [http://dx.doi.org/10.1093/nutrit/nuy022] [PMID: 29917092] 
[76] World Health Organization. [updated 2018; cited 2018 Dec 6]. 
Availbale from: (www.who.int/cancer/en/). 
Is There Something Fishy About Fish Oil Current Pharmaceutical Design, 2019, Vol. 25, No. 15    1757 
[77] Bartsch H, Nair J, Owen RW. Dietary polyunsaturated fatty acids 
and cancers of the breast and colorectum: Emerging evidence for 
their role as risk modifiers. Carcinogenesis 1999; 20(12): 2209-18. 
 [http://dx.doi.org/10.1093/carcin/20.12.2209] [PMID: 10590211] 
[78] Abel S, Riedel S, Gelderblom WCA. Dietary PUFA and cancer. 
Proc Nutr Soc 2014; 73(3): 361-7. 
 [http://dx.doi.org/10.1017/S0029665114000585] [PMID: 
24850051] 
[79] Zhang Y, Zhuang P, He W, et al. Association of fish and long-
chain omega-3 fatty acids intakes with total and cause-specific 
mortality: Prospective analysis of 421 309 individuals. J Intern 
Med 2018; 284(4): 399-417. 
 [http://dx.doi.org/10.1111/joim.12786] [PMID: 30019399] 
[80] Li J, Li K, Gao J, et al. Maternal exposure to an n-3 polyunsatu-
rated fatty acid diet decreases mammary cancer risk of female off-
spring in adulthood. Food Funct 2018; 9(11): 5768-77. 
 [http://dx.doi.org/10.1039/C8FO01006D] [PMID: 30327803] 
[81] Mikirova N, Riordan HD, Jackson JA, Wong K, Miranda-Massari 
JR, Gonzalez MJ. Erythrocyte membrane fatty acid composition in 
cancer patients. P R Health Sci J 2004; 23(2): 107-13. 
 [PMID: 15377058] 
[82] Coviello G, Tutino V, Notarnicola M, Caruso MG. Erythrocyte 
membrane fatty acids profile in colorectal cancer patients: A pre-
liminary study. Anticancer Res 2014; 34(9): 4775-9. 
 [PMID: 25202057] 
[83] Camargo CQ, Mocellin MC, Brunetta HS, et al. Fish oil decreases 
the severity of treatment-related adverse events in gastrointestinal 
cancer patients undergoing chemotherapy: A randomized, placebo-
controlled, triple-blind clinical trial. Clin Nutr ESPEN 2019; 31: 
61-70. 
 [http://dx.doi.org/10.1016/j.clnesp.2019.02.015] [PMID: 
31060836] 
[84] Lovegrove C, Ahmed K, Challacombe B, Khan MS, Popert R, 
Dasgupta P. Systematic review of prostate cancer risk and associa-
tion with consumption of fish and fish-oils: Analysis of 495,321 
participants. Int J Clin Pract 2015; 69(1): 87-105. 
 [http://dx.doi.org/10.1111/ijcp.12514] [PMID: 25495842] 
[85] Luu HN, Cai H, Murff HJ, et al. A prospective study of dietary 
polyunsaturated fatty acids intake and lung cancer risk. Int J Cancer 
2018; 143(9): 2225-37. 
 [http://dx.doi.org/10.1002/ijc.31608] [PMID: 29905376] 
[86] Volpato M, Hull MA. Omega-3 polyunsaturated fatty acids as 
adjuvant therapy of colorectal cancer. Cancer Metastasis Rev 2018; 
37(2-3): 545-55. 
 [http://dx.doi.org/10.1007/s10555-018-9744-y] [PMID: 29971573] 
[87] Song M, Zhang X, Meyerhardt JA, et al. Marine ω-3 polyunsatu-
rated fatty acid intake and survival after colorectal cancer diagno-
sis. Gut 2017; 66(10): 1790-6. 
 [http://dx.doi.org/10.1136/gutjnl-2016-311990] [PMID: 27436272] 
[88] Cockbain AJ, Toogood GJ, Hull MA. ω-3 polyunsaturated fatty 
acids for the treatment and prevention of colorectal cancer. Gut 
2012; 61(1): 135-49. 
 [http://dx.doi.org/10.1136/gut.2010.233718] [PMID: 21490374] 
[89] Bougnoux P, Hajjaji N, Ferrasson MN, Giraudeau B, Couet C, Le 
Floch O. Improving outcome of chemotherapy of metastatic breast 
cancer by docosahexaenoic acid: A phase II trial. Br J Cancer 2009; 
101(12): 1978-85. 
 [http://dx.doi.org/10.1038/sj.bjc.6605441] [PMID: 19920822] 
[90] Murphy RA, Mourtzakis M, Chu QS, Baracos VE, Reiman T, 
Mazurak VC. Supplementation with fish oil increases first-line 
chemotherapy efficacy in patients with advanced nonsmall cell 
lung cancer. Cancer 2011; 117(16): 3774-80. 
 [http://dx.doi.org/10.1002/cncr.25933] [PMID: 21328326] 
[91] Ma YJ, Yu J, Xiao J, Cao BW. The consumption of ω-3 polyun-
saturated fatty acids improves clinical outcomes and prognosis in 
pancreatic cancer patients: A systematic evaluation. Nutr Cancer 
2015; 67(1): 112-8. 
 [http://dx.doi.org/10.1080/01635581.2015.976315] [PMID: 
25425246] 
[92] Fuentes NR, Kim E, Fan YY, Chapkin RS. Omega-3 fatty acids, 
membrane remodeling and cancer prevention. Mol Aspects Med 
2018; 64: 79-91. 
 [http://dx.doi.org/10.1016/j.mam.2018.04.001] [PMID: 29627343] 
[93] Miccadei S, Masella R, Mileo AM, Gessani S. ω3 Polyunsaturated 
Fatty Acids as Immunomodulators in Colorectal Cancer: New Po-
tential Role in Adjuvant Therapies. Front Immunol 2016; 7: 486. 
 [http://dx.doi.org/10.3389/fimmu.2016.00486] [PMID: 27895640] 
[94] Thursby E, Juge N. Introduction to the human gut microbiota. 
Biochem J 2017; 474(11): 1823-36. 
 [http://dx.doi.org/10.1042/BCJ20160510] [PMID: 28512250] 
[95] Gilbert JA, Blaser MJ, Caporaso JG, Jansson JK, Lynch SV, 
Knight R. Current understanding of the human microbiome. Nat 
Med 2018; 24(4): 392-400. 
 [http://dx.doi.org/10.1038/nm.4517] [PMID: 29634682] 
[96] Carding S, Verbeke K, Vipond DT, Corfe BM, Owen LJ. Dysbiosis 
of the gut microbiota in disease. Microb Ecol Health Dis 2015; 26: 
26191. 
 [PMID: 25651997] 
[97] Flint HJ, Duncan SH, Louis P. The impact of nutrition on intestinal 
bacterial communities. Curr Opin Microbiol 2017; 38: 59-65. 
 [http://dx.doi.org/10.1016/j.mib.2017.04.005] [PMID: 28486162] 
[98] Costantini L, Molinari R, Farinon B, Merendino N. Impact of 
Omega-3 Fatty Acids on the Gut Microbiota. Int J Mol Sci 2017; 
18(12): 2645-63. 
 [http://dx.doi.org/10.3390/ijms18122645] [PMID: 29215589] 
[99] Menni C, Zierer J, Pallister T, et al. Omega-3 fatty acids correlate 
with gut microbiome diversity and production of N-
carbamylglutamate in middle aged and elderly women. Sci Rep 
2017; 7(1): 11079. 
 [http://dx.doi.org/10.1038/s41598-017-10382-2] [PMID: 
28894110] 
[100] Cândido FG, Valente FX, Grześkowiak LM, Moreira APB, Rocha 
DMUP, Alfenas RCG. Impact of dietary fat on gut microbiota and 
low-grade systemic inflammation: Mechanisms and clinical impli-
cations on obesity. Int J Food Sci Nutr 2018; 69(2): 125-43. 
 [http://dx.doi.org/10.1080/09637486.2017.1343286] [PMID: 
28675945] 
[101] Watson H, Mitra S, Croden FC, et al. A randomised trial of the 
effect of omega-3 polyunsaturated fatty acid supplements on the 
human intestinal microbiota. Gut 2018; 67(11): 1974-83. 
 [http://dx.doi.org/10.1136/gutjnl-2017-314968] [PMID: 28951525] 
[102] Global Iniative For Asthma (GINA). Pocket Guide for Astma Man-
agement and Prevention (for adults and Children Older than 5 
Years). A Pocket Guide for Health Professionals. [updated 2018; 
cited 2018 Dec 1]. Available from: Https://ginasthma.org/2018-
pocket-guide-for-asthma-management-and-prevention/. 
[103] Hall S, Agrawal DK. Key mediators in the immunopathogenesis of 
allergic asthma. Int Immunopharmacol 2014; 23(1): 316-29. 
 [http://dx.doi.org/10.1016/j.intimp.2014.05.034] [PMID: 
24933589] 
[104] Miyata J, Arita M. Role of omega-3 fatty acids and their metabo-
lites in asthma and allergic diseases. Allergol Int 2015; 64(1): 27-
34. 
 [http://dx.doi.org/10.1016/j.alit.2014.08.003] [PMID: 25572556] 
[105] Olsen SF, Østerdal ML, Salvig JD, et al. Fish oil intake compared 
with olive oil intake in late pregnancy and asthma in the offspring: 
16 y of registry-based follow-up from a randomized controlled 
trial. Am J Clin Nutr 2008; 88(1): 167-75. 
 [http://dx.doi.org/10.1093/ajcn/88.1.167] [PMID: 18614738] 
[106] Bisgaard H, Stokholm J, Chawes BL, et al. Fish oil-derived fatty 
acids in pregnancy and wheeze and asthma in offspring. N Engl J 
Med 2016; 375(26): 2530-9. 
 [http://dx.doi.org/10.1056/NEJMoa1503734] [PMID: 28029926] 
[107] Damsgaard CT, Lauritzen L, Kjaer TM, et al. Fish oil supplementa-
tion modulates immune function in healthy infants. J Nutr 2007; 
137(4): 1031-6. 
 [http://dx.doi.org/10.1093/jn/137.4.1031] [PMID: 17374672] 
[108] Best KP, Gold M, Kennedy D, Martin J, Makrides M. Omega-3 
long-chain PUFA intake during pregnancy and allergic disease out-
comes in the offspring: A systematic review and meta-analysis of 
observational studies and randomized controlled trials. Am J Clin 
Nutr 2016; 103(1): 128-43. 
 [http://dx.doi.org/10.3945/ajcn.115.111104] [PMID: 26675770] 
[109] Abdulrazaq M, Innes JK, Calder PC. Effect of ω-3 polyunsaturated 
fatty acids on arthritic pain: A systematic review. Nutrition 2017; 
39-40: 57-66. 
1758    Current Pharmaceutical Design, 2019, Vol. 25, No. 15 Šunderić et al. 
 [http://dx.doi.org/10.1016/j.nut.2016.12.003] [PMID: 28606571] 
[110] Musumeci G. The effect of mechanical loading on articular carti-
lage. J Funct Morphol Kinesiol 2016; 1: 154-61. 
 [http://dx.doi.org/10.3390/jfmk1020154] 
[111] Kaneko Y, Takeuchi T. A paradigm shift in rheumatoid arthritis 
over the past decade. Intern Med 2014; 53(17): 1895-903. 
 [http://dx.doi.org/10.2169/internalmedicine.53.2834] [PMID: 
25175120] 
[112] Reynard LN, Loughlin J. Genetics and epigenetics of osteoarthritis. 
Maturitas 2012; 71(3): 200-4. 
 [http://dx.doi.org/10.1016/j.maturitas.2011.12.001] [PMID: 
22209350] 
[113] Brandt KD, Dieppe P, Radin EL. Etiopathogenesis of osteoarthritis. 
Rheum Dis Clin North Am 2008; 34(3): 531-59. 
 [http://dx.doi.org/10.1016/j.rdc.2008.05.011] [PMID: 18687271] 
[114] Woo SJ, Lim K, Park SY, et al. Endogenous conversion of n-6 to 
n-3 polyunsaturated fatty acids attenuates K/BxN serum-transfer 
arthritis in fat-1 mice. J Nutr Biochem 2015; 26(7): 713-20. 
 [http://dx.doi.org/10.1016/j.jnutbio.2015.01.011] [PMID: 
25910895] 
[115] Bannenberg G, Arita M, Serhan CN. Endogenous receptor ago-
nists: Resolving inflammation. ScientificWorldJournal 2007; 7: 
1440-62. 
 [http://dx.doi.org/10.1100/tsw.2007.188] [PMID: 17767360] 
[116] Landewé R, van der Heijde D, van der Linden S, Boers M. Twenty-
eight-joint counts invalidate the DAS28 remission definition owing 
to the omission of the lower extremity joints: A comparison with 
the original DAS remission. Ann Rheum Dis 2006; 65(5): 637-41. 
 [http://dx.doi.org/10.1136/ard.2005.039859] [PMID: 16219709] 
[117] Rajaei E, Mowla K, Ghorbani A, Bahadoram S, Bahadoram M, 
Dargahi-Malamir M. The Effect of Omega-3 Fatty Acids in Pa-
tients With Active Rheumatoid Arthritis Receiving DMARDs 
Therapy: Double-Blind Randomized Controlled Trial. Glob J 
Health Sci 2015; 8(7): 18-25. 
 [http://dx.doi.org/10.5539/gjhs.v8n7p18] [PMID: 26925896] 
[118] Veselinovic M, Vasiljevic D, Vucic V, et al. Clinical Benefits of n-
3 PUFA and ɤ-Linolenic Acid in Patients with Rheumatoid Arthri-
tis. Nutrients 2017; 25: 9(4). 
[119] Woodman RJ, Baghdadi LR, Shanahan EM, de Silva I, Hodgson 
JM, Mangoni AA. Diets high in n-3 fatty acids are associated with 
lower arterial stiffness in patients with rheumatoid arthritis: A la-
tent profile analysis. Br J Nutr 2019; 121(2): 182-94. 
 [http://dx.doi.org/10.1017/S0007114518003100] [PMID: 
30430957] 
[120] Gioxari A, Kaliora AC, Marantidou F, Panagiotakos DP. Intake of 
ω-3 polyunsaturated fatty acids in patients with rheumatoid arthri-
tis: A systematic review and meta-analysis. Nutrition 2018; 45: 
114-124.e4. 
 [http://dx.doi.org/10.1016/j.nut.2017.06.023] [PMID: 28965775] 
[121] Di Giuseppe D, Wallin A, Bottai M, Askling J, Wolk A. Long-term 
intake of dietary long-chain n-3 polyunsaturated fatty acids and risk 
of rheumatoid arthritis: A prospective cohort study of women. Ann 
Rheum Dis 2014; 73(11): 1949-53. 
 [http://dx.doi.org/10.1136/annrheumdis-2013-203338] [PMID: 
23940215] 
[122] Philippou E, Nikiphorou E. Are we really what we eat? Nutrition 
and its role in the onset of rheumatoid arthritis. Autoimmun Rev 
2018; 17(11): 1074-7. 
 [http://dx.doi.org/10.1016/j.autrev.2018.05.009] [PMID: 
30213695] 
[123] Parr CL, Magnus MC, Karlstad Ø, et al. Vitamin A and D intake in 
pregnancy, infant supplementation, and asthma development: The 
Norwegian Mother and Child Cohort, Am J Clin Nutrn, 107 (5); 
789-98.  
[124] Bastie JN, Balitrand N, Guidez F, et al. 1 alpha,25-
dihydroxyvitamin D3 transrepresses retinoic acid transcriptional 
activity via vitamin D receptor in myeloid cells. Mol Endocrinol 
2004; 18(11): 2685-99. 
 [http://dx.doi.org/10.1210/me.2003-0412] [PMID: 15284334] 
[125] Roy J, Oger C, Thireau J, et al. Nonenzymatic lipid mediators, 
neuroprostanes, exert the antiarrhythmic properties of docosahex-
aenoic acid. Free Radic Biol Med 2015; 86: 269-78. 
 [http://dx.doi.org/10.1016/j.freeradbiomed.2015.04.014] [PMID: 
25911196] 
[126] He K, Rimm EB, Merchant A, et al. Fish consumption and risk of 
stroke in men. JAMA 2002; 288(24): 3130-6. 
 [http://dx.doi.org/10.1001/jama.288.24.3130] [PMID: 12495393] 
[127] Driss F, Vericel E, Lagarde M, Dechavanne M, Darcet P. Inhibition 
of platelet aggregation and thromboxane synthesis after intake of 
small amount of icosapentaenoic acid. Thromb Res 1984; 36(5): 
389-96. 
 [http://dx.doi.org/10.1016/0049-3848(84)90295-0] [PMID: 
6098051] 
[128] Folsom AR, Demissie Z. Fish intake, marine omega-3 fatty acids, 
and mortality in a cohort of postmenopausal women. Am J Epide-
miol 2004; 160(10): 1005-10. 
 [http://dx.doi.org/10.1093/aje/kwh307] [PMID: 15522857] 
[129] Järvinen R, Knekt P, Rissanen H, Reunanen A. Intake of fish and 
long-chain n-3 fatty acids and the risk of coronary heart mortality 
in men and women. Br J Nutr 2006; 95(4): 824-9. 
 [http://dx.doi.org/10.1079/BJN20051687] [PMID: 16571163] 
[130] Streppel MT, Ocké MC, Boshuizen HC, Kok FJ, Kromhout D. 
Long-term fish consumption and n-3 fatty acid intake in relation to 
(sudden) coronary heart disease death: The Zutphen study. Eur 
Heart J 2008; 29(16): 2024-30. 
 [http://dx.doi.org/10.1093/eurheartj/ehn294] [PMID: 18641046] 
[131] de Goede J, Geleijnse JM, Boer JM, Kromhout D, Verschuren 
WM. Marine (n-3) fatty acids, fish consumption, and the 10-year 
risk of fatal and nonfatal coronary heart disease in a large popula-
tion of Dutch adults with low fish intake. J Nutr 2010; 140(5): 
1023-8. 
 [http://dx.doi.org/10.3945/jn.109.119271] [PMID: 20335635] 
[132] Rhee JJ, Kim E, Buring JE, Kurth T. Fish consumption, omega-3 
fatty acids, and risk of cardiovascular disease. Am J Prev Med 
2017; 52(1): 10-9. 
 [http://dx.doi.org/10.1016/j.amepre.2016.07.020] [PMID: 
27646568] 
[133] Harris WS. Are n-3 fatty acids still cardioprotective? Curr Opin 
Clin Nutr Metab Care 2013; 16(2): 141-9. 
 [http://dx.doi.org/10.1097/MCO.0b013e32835bf380] [PMID: 
23196817] 
[134] Rauch B, Schiele R, Schneider S, et al. OMEGA, a randomized, 
placebo-controlled trial to test the effect of highly purified omega-3 
fatty acids on top of modern guideline-adjusted therapy after myo-
cardial infarction. Circulation 2010; 122(21): 2152-9. 
 [http://dx.doi.org/10.1161/CIRCULATIONAHA.110.948562] 
[PMID: 21060071] 
[135] Bosch J, Gerstein HC, Dagenais GR, et al. n-3 fatty acids and car-
diovascular outcomes in patients with dysglycemia. N Engl J Med 
2012; 367(4): 309-18. 
 [http://dx.doi.org/10.1056/NEJMoa1203859] [PMID: 22686415] 
[136] Aung T, Halsey J, Kromhout D, et al. Associations of Omega-3 
Fatty Acid Supplement Use With Cardiovascular Disease Risks: 
Meta-analysis of 10 Trials Involving 77 917 Individuals. JAMA 
Cardiol 2018; 3(3): 225-34. 
 [http://dx.doi.org/10.1001/jamacardio.2017.5205] [PMID: 
29387889] 
[137] Chen C, Yang Y, Yu X, Hu S, Shao S. Association between 
omega-3 fatty acids consumption and the risk of type 2 diabetes: A 
meta-analysis of cohort studies. J Diabetes Investig 2017; 8(4): 
480-8. 
 [http://dx.doi.org/10.1111/jdi.12614] [PMID: 28032469] 
[138] Daenen LG, Cirkel GA, Houthuijzen JM, et al. Increased plasma 
levels of chemoresistance-inducing fatty acid 16:4(n-3) after con-
sumption of fish and fish oil. JAMA Oncol 2015; 1(3): 350-8. 
 [http://dx.doi.org/10.1001/jamaoncol.2015.0388] [PMID: 
26181186] 
[139] Weylandt KH, Serini S, Chen YQ, et al. Omega-3 Polyunsaturated 
Fatty Acids: The Way Forward in Times of Mixed Evidence. Bio-
Med Res Int 2015; 2015: 143109. 
 [http://dx.doi.org/10.1155/2015/143109] [PMID: 26301240] 
[140] Chua ME, Sio MC, Sorongon MC, Dy JS. Relationship of dietary 
intake of omega-3 and omega-6 Fatty acids with risk of prostate 
cancer development: A meta-analysis of prospective studies and 
review of literature. Prostate Cancer 2012; 2012: 826254. 
Is There Something Fishy About Fish Oil Current Pharmaceutical Design, 2019, Vol. 25, No. 15    1759 
 [http://dx.doi.org/10.1155/2012/826254] [PMID: 23193480] 
[141] Haas-Haseman M. Weighing the Benefits of Fish Oil for Patients 
With Prostate Cancer: A Subcohort Review From the SELECT 
Trial. J Adv Pract Oncol 2015; 6(4): 376-8. 
 [PMID: 26705498] 
[142] Stark KD, Van Elswyk ME, Higgins MR, Weatherford CA, Salem 
N Jr. Global survey of the omega-3 fatty acids, docosahexaenoic 
acid and eicosapentaenoic acid in the blood stream of healthy 
adults. Prog Lipid Res 2016; 63: 132-52. 
 [http://dx.doi.org/10.1016/j.plipres.2016.05.001] [PMID: 
27216485] 
[143] Nakamura Y, Ueshima H, Okamura T, et al. Association between 
fish consumption and all-cause and cause-specific mortality in Ja-
pan: NIPPON DATA80, 1980-99. Am J Med 2005; 118(3): 239-
45. 
 [http://dx.doi.org/10.1016/j.amjmed.2004.12.016] [PMID: 
15745721] 
[144] von Schacky C. Omega-3 Index and sudden cardiac death. Nutri-
ents 2010; 2(3): 375-88. 
 [http://dx.doi.org/10.3390/nu2030375] [PMID: 22254028] 
[145] Elvevoll EO, Osterud B. Impact of processing on nutritional quality 
of marine food items. Forum Nutr 2003; 56: 337-40. 
 [PMID: 15806925] 
[146] Clayton PR, Ladi S. From alga to omega; have we reached peak 
(fish) oil? J R Soc Med 2015; 108(9): 351-7. 
 [http://dx.doi.org/10.1177/0141076815599673] [PMID: 26359136] 
[147] Harris WS, Pottala JV, Sands SA, Jones PG. Comparison of the 
effects of fish and fish-oil capsules on the n 3 fatty acid content of 
blood cells and plasma phospholipids. Am J Clin Nutr 2007; 86(6): 
1621-5. 
 [http://dx.doi.org/10.1093/ajcn/86.6.1621] [PMID: 18065578] 
 
 
